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Summary Epidemiological studies reveal fracture incidence in epilepsy is twice
that of the normal population. Much interest has been focused on Vitamin D, however,
considering mixed results on non-enzyme inducing anti-epileptic drugs (AEDs) and
bone mineral density (BMD) additional metabolic effects may be to blame. AEDs
increase serum homocysteine (s-Hcy) by lowering blood folate levels. An association
between elevated homocysteine, BMD and increased fracture incidence has been
found in non-epilepsy populations. Additionally, folate and Vitamin B12 levels are
independently related to bone mineral density in various non-epilepsy populations.
This study supports previous research, which found elevated s-Hcy in subjects taking
AEDs and that bone loss is related to the use of enzyme-inducing AEDs and changes in
alkaline phosphatase. By one-way ANOVA, subjects on phenytoin monotherapy had
significantly higher levels of s-Hcy than those on other AEDs (F = 5.89, p = .016).
Regression analyses revealed homocysteine, fracture history, length of years on AEDs,
ethnicity were predictors of spine T scores. Weight and BMI were predictors of both
BMD and DEXATscores. Use of enzyme-inducing AEDs was a negative predictor of spine
BMD and Tscores, while phenytoinmonotherapy was a positive predictor of spine BMD.
Lamotrigine was found to be a negative predictor of spine Tscore. Ambulatory status,
menopause and alcohol consumption were predictors of BMD but not T scores. In this
study, persons with epilepsy who take nutritional supplementation have 25% lower
s-Hcy levels than those who do not. Supplementation continues to be important in
preventative epilepsy care.
# 2006 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.* Corresponding author. Tel.: +1 614 293 3734;
fax: +1 614 293 6667.
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Osteoporosis is a common bone disease affecting up
to 40% of women and 12% of men.1 An estimated 1.5
million people suffer a bone-disease related frac-
ture annually in the U.S.2 Hip fractures account
for most of the morbidity, mortality and costs of
the disease.3 Costs for the treatment of incident. Published by Elsevier Ltd. All rights reserved.
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billion in 2004, U.S. dollars.4 Up to 20—30% of
postmenopausal women and 50% of men have a
secondary cause (i.e. drug therapies, endocrine
disorders, eating disorders and immobilization) of
osteoporosis.5 Bone loss can occur after as little as
two years of antiepileptic drug (AED) exposure6,7
and epidemiological studies have found the inci-
dence of fracture in epilepsy to be twice that of
the normal population.8,9 While osteoporosis is gen-
erally associated with advancing age it also impacts
individuals who are unable to reach optimal bone
density during childhood and adolescence,10 so per-
sons with childhood onset epilepsy may be espe-
cially at risk. Whether these changes are primary
due to AED treatment or lack of physical activity or a
combination of the two is not presently known.7
In a study of older women, it was found that those
who were continuous users of enzyme-inducing AEDs
(phenytoin, phenobarbital, carbamazepine and pri-
midone) had almost double the amount of bone loss
at the calcaneus and the total hip on DEXA compared
to nonusers.11 Younger men (age 25—44) on AEDs
(phenytoin, carbamazepine, phenobarbital, val-
proic acid and gabapentin) have been found to have
a 1.8% annual loss of bone mineral density (BMD),
yielding a 2.5 fold increased prevalence of bone loss
at the hip when compared to the healthy U.S. male
population.12 Pack et al. found that persons with
epilepsy, taking enzyme-inducing AEDs, are prone to
significant loss of bonemass (based on current World
Health Organization guidelines); with only 42% hav-
ing normal bone density compared to 84% expected
in the normal population.13 Bone loss in epilepsy has
been traditionally thought to be as a result of
Vitamin D deficiency, secondary to enzyme-inducing
AED use.13 Results of non-enzyme inducing antiepi-
leptic drugs such as valproic acid and lamotrigine on
bone have in the past been mixed.14—16 It follows
that mechanisms other than Vitamin D may also be
involved in the pathogenesis of osteoporosis by
AEDs.
Homocysteine, a key intermediate in methionine
metabolism, is created as a byproduct of methyl
transfer reactions important for the synthesis of
nucleic acids, methylated protein, neurotransmit-
ters and phospholipids.17 Anti-epileptic drugs (AEDs)
have been shown to increase serum homocysteine
(s-Hcy) by lowering blood folate levels.18—23 The
proposed mechanisms for the folic acid depletion
with AEDs include (1) interference with the intest-
inal absorption of folic acid by increasing the pH (2)
interference with folate transport into tissues, and
(3) Hepatic microsomal induction and increased
folate catabolism.24—26 Valproate and carbamaze-
pine significantly increase homocysteine levelscompared to controls.20,27 Yoo et al. found a 25%
increase in homocysteine in patients taking pheny-
toin and carbamazepine (but not valproic acid)
compared to controls.28
In one study of bone density, for each standard
deviation increase in the homocysteine level, age
and sex-adjusted risk of fracture increased by 30%.29
This level of increased risk is similar to that pre-
viously observed in the risk of cardiovascular disease
and dementia according to homocysteine level.29
Homocysteine levels in the highest quartile double
the risk of fracture.30 Goldbahar et al. found hip and
spine bone mineral density was significantly corre-
lated with plasma homocysteine in postmenopausal
women.31 Homocysteine also appears to predict
fracture rates in patients with Parkinson’s disease.32
Low folate33 and Vitamin B12 levels34 as well as
elevated homocysteine35 are associated with
reduced bone mineral density in post menopausal
women. In addition, low serum B12 has been asso-
ciated with a reduction in bone mineral density
among adolescents fed a macrobiotic diet.36
A homocysteine-associated disturbance in col-
lagen cross-linking has been suggested as a potential
mechanism37,38 and considering the high prevalence
of osteoporosis in homocystinuria (a rare autosomal
recessive disorder), abnormal homocysteine meta-
bolism may contribute to the development of osteo-
porosis.39 Additionally, folate may preserve nitric
oxide synthase activity in bone cells leading to a
stimulation of osteoblast activity while inhibiting
bone catabolism.40 Supplementation with folic acid
and Vitamin B12 has been found to reduce hip
fracture in stroke patients by 20%. This is significant
since both the supplemented group and the control
group had the same number of falls during the follow
up period.41 Furthermore, the administration of
high doses of homocysteine in animal models pro-
duces convulsive seizures.42—44 Therefore, elevated
homocysteine may represent a mechanism by which
the seizure threshold is reduced in some susceptible
patients. This mechanism might be of practical
relevance, as folate is easily supplemented.21
It has been suggested that persons with epilepsy
may have a higher folate requirement to maintain a
normal homocysteine level.28 Also little is known
about homocysteine in African Americans and Lati-
nos with epilepsy. The Center for Disease Control’s
National Health and Nutrition Examination Survey
(NHANES) recently looked at post-folate fortifica-
tion of the U.S. food supply and found a significant
reduction of s-Hcy levels in all ethnic groups.45
However, drug induced elevations of homocysteine
may not respond fully to fortification and supple-
mentation may be necessary. Homocysteine reduc-
tion by vitamin supplementation (folic acid, B6 and
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Table 1 Demographics of participants
Variables n (%)
Female 94 (57)
Ethnicity
African American 75 (46)
Latino 27 (16)B12) could prove to be as simple and elegant a
measure in the reduction of osteoporosis in the
epileptic population as calcium and Vitamin D are
in the elderly. The goal of this study was to see if
there is a relationship between bone loss, homo-
cysteine, demographics (age, gender and ethnicity)
or metabolic factors in epilepsy.Caucasian 60 (36)
Asian/other 3 (2)
On medical assistance 89 (54)
Body mass index
Underweight 6 (4)
Normal 53 (33)
Overweight 39 (24)
Obesity 62 (39)
Ambulatory status
Non ambulant 8 (6)
Ambulant with restrictions 21 (17)
Ambulant without restrictions 61 (48)
Ambulant and exercises 36 (29)
Present smoker 27 (17)
Present drinker 32 (20)
Presence of other
secondary risk factors
30 (18)
History of fracturea 36 (43)
Taking an osteoporosis
medication
19 (16)
Presently taking calcium 52 (32)
Presently taking a multivitamin 76 (46)
Bone density DEXA results
Normal 38 (28)
Osteopenia 59 (43)
Osteoporosis 40 (29)
No DEXA available 28 (17)
AED use
Presently on a enzyme-
inducing AED
78 (47)
Presently on monotherapy
PHT 17 (10)
CBZ 20 (12)
VPA 25 (15)
LTG 16 (10)
Presently on multiple AEDs
Two 33 (35)
Three 13 (13)
Four 1 (2)
Seizure types listed in subject’s medical record
Complex partial 107 (65)
Simple partial 27 (16)
Tonic clonic 38 (23)
Secondary generalized 33 (20)
Absence 9 (5)
Myoclonic 5 (3)
Other (includes not
categorized)
27 (16)
a Fracture information was available on 83 of 165 subjects.Methods
We screened 805 patient charts seen at the Temple
University School of Medicine Department of Neurol-
ogy outpatient epilepsy clinics over the past 2 years.
Dataon165patients, age18years or older (range19—
78), included: age, gender, weight, BMI, ambulatory
status, years on AEDs, current/previous AEDs, serum
levels of homocysteine (s-Hcy), folic acid (s-FA), B12
(s-B12), calcium, alkaline phosphatase, creatinine,
bloodureanitrogen (BUN), supplementationpatterns
anddual-energy x-ray absorptiometry (DEXA) screen-
ing results. Data collection took place over a 1 year
period. Inclusion criteria included patients age 18 or
older, with a diagnosis of epilepsy on AEDs over 2
years. No exclusion criteria were used. Instead doc-
umentation of any secondary causes of osteoporosis,
based on a paper by Fitzpatrick5 was collected to
observe ‘‘what their impact might be.’’ The Temple
University Institutional Review Board approved this
study and since data collection focused on existing
records, written informed consent from each parti-
cipant was not necessary. All data was gathered,
analyzed and stored in a way to protect the patients’
identity and medical information in compliance with
HIPAA and Temple University IRB guidelines.
Certain variables were recoded for analysis. This
included separating serum homocysteine into quar-
tiles as well as performing a log transformation since
values are not normally distributed. Age and years on
AEDswere recodedgenerally intoquartiles inorder to
makecomparisonsbymoreequal group sizes.BMIwas
calculated and recoded based on the National Insti-
tutes of Health website guidelines.46 As a retrospec-
tive study serum homocysteine levels were not
collected as fasting samples. Previous work has found
that non-fasting samples are actually preferable47
and the variation between fasting and non-fasting
samples is not enough to recommend strict fasting
blooddraws.48Bonemineral densitywasmeasuredby
DEXA with the Hologic QDR 1000.
Data analysis plan
The analytic plan of this study followed a specific
progression. Bone mineral density measured in g/
cm2 and the lowest Tscore from each site (excluding
Homocysteine and bone loss in epilepsy 25Ward’s triangle) were the primary dependent
variables. First, descriptive statistics were used to
summarize and describe the data, see Table 1. A
one-way ANOVA analysis of demographics, clinical
measures and DEXA results based on homocysteine
quartiles was performed, see Table 2. One-way
ANOVA analysis was also used to determine if there
were differences in the independent variables: age,
gender, ethnicity, BMI, ambulatory status and length
on time on AEDs, see Table 3. Another one—way
ANOVAwas used to examine various AEDmonothera-
pies and the effects of nutritional supplementation
on DEXA results, see Table 4. Next, we performed a
bivariate (Pearson correlations) analysis to examine
relationships between the dependent and indepen-
dent variables as well as to identify redundancy
among independent variables, see Table 5. Correla-
tions provided insight into the variables which would
likely hold up in the modeling process.
Finally, multivariate regression analysis was per-
formed, see Table 6. Multivariate regression allows
for the examination of multiple independent vari-
ables on each dependent variable. The regression
analysis was performed using a backward serialTable 2 Clinical characteristics of subjects in each quartil
Quartile 1
(n = 41)
Quartile 2
(n = 40)
Age 37.1 (11.5) 45.2 (12.9)
BMI 29.7 (7.8) 28.9 (6.9)
Years on AEDs 20.2 (11.5) 28.2 (15.4)
Serum Hcy 5.9 (1.1) 8.2 (0.6)
Range 2.7—7.2 7.1—9.0
Serum folic acid 17.9 (6.8) 17.9 (6.7)
Serum B12 624.7 (378.2) 655.7 (415.7
Serum calcium 9.2 (0.4) 9.2 (0.4)
Alkaline phosphatase 97.4 (36.9) 94.4 (36.7)
BUN 11.4 (3.9) 14.6 (3.8)
Serum creatinine 0.8 (0.2) 0.9 (0.2)
Spine mineral
density (g/cm2)
.93 (0.28) 1.02 (0.25
Spine T score 1.33 (1.34) 1.25 (1.57
Hip mineral
density (g/cm2)
.81 (.21) .79 (.22)
Hip T Score 0.81 (1.28) 1.47 (1.22
Other osteoporosis risk factors
Yes 7 7
No 34 33
Fracture history
Yes 8 11
No 12 9
NA, not applicable. Other osteoporosis risk factors include; corti
treatment.
* Analysis of variance.
** Chi square.process to eliminate non-significant variables until
only significant ones remained in the model, see
Table 6. Demographic and clinical variables have
been found to be significant predictors of osteo-
porosis. Hence, independent variables included in
the regression analysis included demographics,
medical management factors and clinical markers.
The goal was to determine the degree to which
components from these areas explain bone mineral
density and DEXA T scores for the spine and hip.
SPSS version 13.0 was used for all of the statistical
analyses.Results
This was an adult epilepsy population: mean age: 45
years (S.D. = 13.6, range 18—81), there were 71
males and 94 females. Seventy-five were African
American, 27 Latino, 60 Caucasian and 3 Asian/
Other, average length of AED exposure: 25 years
(S.D. = 14.6, range 1—64). Complete demographics
are displayed in Table 1. DEXA results were found
for 130 patients and homocysteine levels for 158e of homocysteine — mean (standard deviation)
Quartile 3
(n = 39)
Quartile 4
(n = 38)
P value *
48.2 (12.9) 49.6 (14.1) .000
29.6 (6.4) 27.3 (6.2) .382
22.2 (15.6) 26.5 (14.2) .048
10.7 (1.1) 18.3 (7.4) .000
9.1—12.3 12.4—50.0 NA
15.3 (7.2) 12.8 (7.3) .005
) 558.7 (282.4) 493.2 (252.2) .216
9.3 (0.4) 9.3 (0.5) .704
110.2 (57.4) 120.2 (119.2) .355
14.8 (4.5) 15.0 (8.3) .009
1.2 (1.3) 1.1 (0.3) .080
) 1.01 (0.28) .98 (0.20) .514
) 1.12 (1.52) 1.56 (1.78) .724
.83 (.26) .77 (.17) .727
) 0.94 (1.62) 1.50 (0.94) .081
6 7
33 31 .988 **
14 13 .144 **
8 4
costeroid use, thyroid hormone use, eating disorders, cancer
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Table 3 Demographics and bone marker dependent variables — mean (standard deviation)
n Spine
(g/cm2)
Spine T-score Hip
(g/cm2)
Hip T-score Serum
Hcy
Serum
folate
Vitamin B12 Calcium Alkaline
phosphatase
Age
Under 35 43 0.96 (.25) 1.13 (1.17) 0.82 (.20) 1.06 (1.00) 9.20 (5.00) 15.5 (7.4) 578.97 (348.9) 9.4 (0.4) 92.5 (35.0)
36—45 32 1.04 (.22) 1.23 (1.87) 0.78 (.16) 1.04 (1.13) 9.31 (3.99) 17.8 (7.2) 643.61 (384.4) 9.1 (0.3) 121.0 (128.4)
46—54 52 0.98 (.24) 1.15 (1.32) 0.83 (.23) 1.07 (1.49) 11.87 (7.84) 14.6 (7.2) 534.34 (297.7) 9.3 (0.4) 103.2 (47.6)
Over 55 35 0.96 (.28) 1.94 (1.77) 0.74 (.23) 1.69 (1.33) 11.82 (4.16) 17.2 (6.9) 597.10 (341.1) 9.2 (0.5) 113.2 (50.2)
Gender
Male 68 1.03 (.26) 1.23 (1.67) 0.84 (.20) 1.37 (0.98) 11.57 (5.48) 16.6 (7.1) 583.95 (306.4) 9.3 (0.4) 97.8 (39.0)
Female 89 0.96 (.24) 1.42 (1.44) 0.77 (.22) 1.07 (1.49) 9.95 (6.14) 15.6 (7.3) 578.98 (357.4) 9.2 (0.4) 112.1 (85.5)
Ethnicity
African American 74 1.02 (.26) 1.50 (1.65) 0.80 (.22) 1.39 (0.88) 10.87 (6.56) 16.1 (7.8) 612.24 (318.6) 9.3 (0.5) 124.4 (93.4) *
Latino 27 1.04 (.27) 0.99 (1.32) 0.83 (.22) 0.98 (1.38) 12.07 (7.38) 13.6 (6.6) 568.52 (389.4) 9.3 (0.4) 90.5 (30.1) *
Caucasian 57 0.91 (.21) 1.29 (1.50) 0.78 (.20) 1.05 (1.65) 9.75 (3.94) 17.0 (6.6) 551.69 (342.2) 9.3 (0.4) 91.0 (38.9) *
BMI
Underweight 6 0.69 (.38) 2.97 (1.53) ** 0.77 (.06) 1.89 (0.93) *** 9.46 (6.42) 17.6 (7.2) 667.20 (449.3) 9.5 (0.2) 200.2 (288.7) **
Normal weight 52 0.95 (.26) 1.67 (1.38) ** 0.69 (.19) 1.96 (1.14) *** 10.52 (5.38) 16.2 (7.0) 571.66 (245.4) 9.3 (0.5) 100.9 (33.6) **
Overweight 38 0.96 (.19) 1.53 (1.38) ** 0.79 (.17) 1.24 (0.93) *** 12.29 (8.24) 14.8 (7.6) 532.09 (333.0) 9.2 (0.5) 101.3 (55.1) **
Obesity 61 1.06 (.23) 0.80 (1.59) ** 0.89 (.24) -0.53 (1.32) *** 9.80 (4.09) 16.3 (7.3) 583.70 (350.9) 9.3 (0.4) 103.9 (48.3) **
Ambulatory status
Non-ambulatory 6 0.90 (.21) 2.75 (1.32) 0.68 (.16) * 2.22 (.78) ** 11.24 (6.09) 18.44 (8.4) 1065.29 (733.9) ** 9.13 (.57) 202.9 (242.7) ***
Ambulant w/
restrictions
17 0.85 (.31) 1.53 (1.62) 0.67 (.16) * 1.97 (1.53) ** 10.51 (3.88) 18.61 (6.7) 675.16 (444.4) ** 9.21 (.62) 103.1 (52.3) ***
Ambulant w/o
restrictions
49 1.00 (.21) 1.33 (1.18) 0.82 (.23) * 1.00 (1.10) ** 10.16 (4.76) 16.00 (7.1) 542.22 (212.2) ** 9.25 (.37) 103.0 (39.9) ***
Ambulant and
exercises
27 0.97 (.21) 1.10 (1.47) 0.86 (.23) * 0.84 (1.49) ** 10.08 (5.64) 15.55 (7.0) 538.30 (338.1) ** 9.40 (.41) 80.3 (20.8) ***
Length on AEDs
<12 years 40 0.92 (.19) 1.57 (1.23) 0.82 (.26) 1.06 (1.50) 10.50 (5.59) 18.2 (6.3) * 566.45 (282.5) 9.3 (0.5) 106.1 (49.2)
12 to 24 years 40 1.03 (.35) 1.11 (1.86) 0.82 (.22) 0.97 (1.30) 9.95 (4.18) 14.2 (7.6) * 548.31 (238.2) 9.3 (0.4) 101.8 (33.6)
25 to 35 years 36 1.03 (.19) 1.13 (1.56) 0.80 (.16) 1.15 (1.01) 11.16 (8.33) 14.3 (7.4) * 568.09 (391.1) 9.2 (0.5) 117.1 (122.0)
>36 years 38 0.96 (.20) 1.53 (1.47) 0.76 (.21) 1.60 (1.28) 11.11 (5.18) 17.2 (6.9) * 639.00 (411.2) 9.3 (0.3) 99.9 (44.1)
* p < .05.
** p < .01.
*** p < .001.
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Table 4 AEDs, nutritional supplements and bone markers — mean (standard deviation)
n Spine
(g/cm2)
Spine T-Score Hip
(g/cm2)
Hip T-Score Serum Hcy Serum
folate
Serum B12 Calcium Alkaline
phosphate
On PHT monotherapy
No 142 0.98 (.24) 1.28 (1.57) 0.81 (.22) 1.17 (1.35) 10.25 (4.80) * 16.4 (7.1) 593.1 (348.5) 9.3 (0.4) * 101.2 (69.5) *
Yes 16 1.05 (.32) 1.81 (1.22) 0.73 (.15) 1.48 (0.70) 14.16 (11.54) * 13.1 (7.4) 472.2 (180.9) 9.0 (0.4) * 146.8 (61.7) *
On CBZ monotherapy
No 142 0.99 (.24) 1.26 (1.62) 0.79 (.21) 1.19 (1.39) 10.84 (6.02) 15.9 (7.2) 580.9 (337.0) 9.3 (0.5) 107.7 (74.7)
Yes 17 0.97 (.31) 1.57 (1.48) 0.88 (.20) 0.83 (0.72) 8.96 (4.61) 17.1 (7.1) 602.1 (408.4) 9.3 (0.3) 97.7 (24.6)
On VPA monotherapy
No 133 0.98 (.25) 1.41 (1.61) 0.79 (.22) 1.23 (1.33) 10.55 (5.92) 15.9 (7.2) 549.4 (307.2) ** 9.2 (0.4) ** 110.6 (72.6) *
Yes 24 1.07 (.18) 0.86 (1.07) 0.83 (.20) 0.98 (0.93) 11.16 (5.89) 17.0 (7.4) 758.0 (438.9) ** 9.5 (0.4) ** 79.5 (44.5) *
On LTG monotherapy
No 143 0.99 (.26) 1.47 (1.74) 0.80 (.21) 1.25 (1.18) 10.88 (6.10) 15.9 (7.3) 582.2 (349.3) 9.2 (0.4) * 107.3 (73.1)
Yes 15 0.94 (.17) 1.32 (1.52) 0.78 (.27) 0.87 (1.96) 8.43 (2.64) 17.0 (6.6) 568.5 (186.4) 9.5 (0.4) * 95.6 (28.3)
Presently taking a multivitamin
No 88 1.00 (.22) 1.37 (1.51) 0.83 (.22) 1.09 (1.04) 12.03 (7.15) ** 13.9 (7.4) ** 503.6 (308.2) ** 9.3 (0.5) 113.2 (89.2)
Yes 76 0.96 (.27) 1.31 (1.59) 0.76 (.20) 1.32 (1.53) 9.11 (3.57) ** 18.4 (6.3) ** 670.9 (351.3) ** 9.3 (0.4) 98.0 (37.8)
Presently taking calcium
No 112 1.00 (.25) 1.27 (1.62) 0.82 (.22) 1.15 (1.08) 10.53 (4.91) 15.6 (7.4) 574.4 (331.3) 9.3 (0.4) 107.6 (79.4)
Yes 52 0.95 (.25) 1.47 (1.37) 0.76 (.21) 1.29 (1.65) 10.92 (7.61) 16.7 (6.8) 594.5 (354.5) 9.2 (0.6) 102.9 (45.8)
Alkaline phosphate — serum alkaline phosphatase.
* p < .05.
** p < .01.
*** p < .001.*
*
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Table 5 Pearson correlation matrix of demographics/laboratory variables
Variables Spine (g/cm2) Spine T score Hip (g/cm2) Hip T score
Age 0.04 0.16 0.13 0.19 *
Gender 0.14 0.06 0.17 0.12
Ethnicity 0.18 * 0.07 0.03 0.12
Body weight 0.31 *** 0.37 *** 0.36 *** 0.47 ***
Body mass index 0.25 ** 0.29 *** 0.30 *** 0.45 ***
Ambulatory status 0.13 0.24 * 0.28 ** 0.31 **
Years on AEDs 0.04 0.02 0.10 0.17
Presently on enzyme-
inducing AEDs
0.03 0.15 0.05 0.16
Presently taking a
multivitamin
0.08 0.02 0.16 0.09
Presently taking calcium 0.11 0.06 0.13 0.05
Fracture history 0.04 0.13 0.01 0.08
Present smoker 0.24 ** 0.11 0.07 0.04
Present drinker 0.02 0.11 0.28 ** 0.18 *
Menopause status 0.22 0.17 0.28 ** 0.12
Presence of other
risk factors
0.10 0.07 0.09 0.07
s-Hcy 0.09 0.02 0.08 0.10
log-Hcy 0.06 0.05 0.06 0.11
s-FA 0.09 0.09 0.01 0.03
s-B12 0.13 0.16 0.01 0.13
Serum calcium 0.08 0.09 0.16 0.07
Serum alkaline phosphatase 0.09 0.26 ** 0.06 0.06
BUN 0.08 0.05 0.02 0.04
Serum creatinine 0.12 0.04 0.10 0.03
* p  .05.
** p  .01.
*** p  .001.patients. Of the 130 subjects who obtained a DEXA
scan of the spine 40 had osteopenia (men = 14,
women = 26) and 30 had osteoporosis (men = 14,
women = 16) and 60 were normal (men = 28,
women = 32). For those who had a DEXA of the
hip 64 had osteopenia (men = 33, women = 31), 13
had osteoporosis (men = 6, women = 7) and 52 were
normal (men = 17, women = 35). We were able to
determine from extensive historical chart review
that 47 subjects had a history of fracture (African
American = 18, Latino = 3 and Caucasian = 26) and
36 did not (African American = 17, Latino = 7 and
Caucasian = 12).
Clinical characteristics by quartile of
homocysteine
Clinical characteristics were separated by quar-
tiles of homocysteine. Age was significantly higher
in the ascending quartiles (F = 7.46, p = .000) by
one-way ANOVA, see Table 2. Years on AEDs were
higher in quartiles 2 and 4 compared with 1 and 4
but this was not significant. Serum folate levels
were significantly lower in each successive quartile(F = 4.42, p = .005). BUN levels also rose with each
increment the in homocysteine quartile (F = 4.01,
p = .009). There were no significant differences
in the presence of other osteoporosis risk factors
in each quartile (Chi square = .132, p = .988). No
significant increase in fracture history was noted
in successive quartiles (Chi square = 5.41,
p = .144).
Dependent variables: Bone density and
DEXA T scores
Analysis by one-way ANOVA indicated no significant
differences in spine mineral density, spine DEXA T-
scores, hip mineral density and hip DEXA T-scores
based on age, gender or ethnicity, see Table 3. Mean
s-Hcy levels in mmol/L (S.D.) were 10.9 (6.6) for
African Americans, 12.1 (7.4) Latinos, 9.8 (3.9)
Caucasians and 9.8 (4.8) for Asian/Other. One-way
ANOVA revealed no significant differences between
s-Hcy (F = 1.00, p = .39), s-FA (F = 1.25, p = .29), s-
B12 (F = .33, p = .80) and ethnicity, see Table 3.
There was a trend towards significance for homo-
cysteine and age (F = 2.64, p = .051) that became
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Table 6 Multivariate regression analysis summary
Measure Spine mineral densi-
tya
Spine T scoreb Hip mineral densityc Hip T scored
B Beta B Beta B Beta B Beta
Gender (Male = 0,
female = 1)
— 1.321 .427 **** — —
Weight Scale .002 .307 *** — — .014 .447 ****
BMI (category) Ordinal — .547 .340 *** .066 .314 **** —
Ethnicity Ordinal — .855 .534 **** — —
Taking calcium
supplements
(No = 0, yes = 1) — .567 .182 * — —
Menopause (No = 0, yes = 1) — — .251 .399 **** —
Present drinker (No = 0, yes = 1) — — .118 .222 ** —
Ambulatory status Ordinal — — .060 .241 ** .391 .239 **
Other risk factors (No = 0, yes = 1) — — — .633 .190 **
History of fracture (No = 0, yes = 1) — .608 .197 * — —
Years on AEDs Scale — .041 .393 **** — —
On enzyme-inducing AED (No = 0, yes = 1) .050 .173 * 1.196 .390 *** — —
On PHT monotherapy (No = 0, yes = 1) .235 .305 *** — — —
On LTG monotherapy (No = 0, yes = 1) — 1.067 .239 ** .131 .208 ** —
Blood urea nitrogen Scale — .057 .202 * — —
Serum alkaline phosphatase Scale — .005 .321 ** — —
Log serum homocysteine Scale — 3.492 .801 *** — —
Homocysteine quartile Ordinal — 1.141 .769 *** — —
Spine and hip mineral density are measured in g/cm2; BMI category coded a underweight = 0, normal weight = 1, overweight = obesity = 3; ethnicity was coded as African American = 0,
Latino = 1, Caucasian = 2, Asian/other = 3; ambulatory status was coded as non-ambulant = 1, ambulant w/restrictions = 2, amb nt w/o restrictions = 3, ambulant and exercises = 4; serum
homocysteine was recoded in the following quartiles: quartile 1 = 2.7—7.2, quartile 2 = 7.3—9.0, quartile 3 = 9.1—12.3, quar 4 = 12.4—50.0.
* p  .10.
** p  .05.
*** p  .01.
**** p  .001.
a R2 = 0.12, F = 2.99, n = 99, p = .007.
b R2 = 0.50, F = 6.30, n = 58, p = .000.
c R2 = 0.48, F = 6.71, n = 83, p = .000.
d R2 = 0.36, F = 6.08, n = 93, p = .000.2,
ula
tile
30 J.O. Elliott et al.significant when log transformed (F = 4.15,
p = .007).
Analysis of BMI, by one-way ANOVA, found sig-
nificant differences in spine T-score (F = 5.15,
p = .002), hip T-score (F = 11.71, p = .000) and
serum alkaline phosphatase (F = 3.94, p = .010).
Ambulatory status was significant for hip mineral
density (F = 2.82, p = .044), hip t-score (F = 4.17,
p = .008), Vitamin B12 level (F = 5.34, p = .002) and
serum alkaline phosphatase (F = 6.76, p = .000).
Length on time on AEDs was only significant for
serum folate (F = 3.20, p = .025).
AED monotherapy and supplementation
results
By one-way ANOVA, subjects on phenytoin mono-
therapy had significantly higher levels of s-Hcy than
those on other AEDs (F = 5.89, p = .016), see Table 4.
Persons on valproic acid monotherapy had signifi-
cantly higher levels of Vitamin B12 (F = 7.13,
p = .008), serum calcium (F = 7.83, p = .006) and
lower serum alkaline phosphatase (F = 4.02,
p = .047). Subjects taking a multivitamin had sig-
nificantly lower serum homocysteine (F = 10.09,
p = .002) as well as higher serum folic acid
(F = 15.61, p = .000) and serum Vitamin B12 levels
(F = 8.89, p = .003). Only seven subjects had s-FA
below the laboratory normal range of 5.4 ng/ml.
Multivitamin and calcium supplementation had no
significant effect on bone markers.
Bivariate analysis
Pearson bivariate correlation analysis on all vari-
ables was performed. Spine and hip mineral density
and DEXA T scores were not significantly correlated
with s-Hcy. Serum alkaline phosphatase was inver-
sely correlated with spine T score (r = .26,
p = .004). Surprisingly, length of years on AEDs
was not correlated with spine T score (r = .015,
p = .865) or hip T score (r = 0.16, p = .057). As
expected, body weight and BMI were significantly
correlated with bone mineral density and DEXA T
scores. Ambulatory status was significantly corre-
lated with spine T score (r = .24, p = .019), hip
mineral density (r = .28, p = .008) and hip T score
(r = .31, p = .002), see Table 5.
Age was the only demographic variable corre-
lated with s-Hcy (r = .19, p = .02). For those cur-
rently taking enzyme-inducing AEDs (PHT, CBZ, PB,
OXC, PRM) there was an inverse correlation with
serum calcium (r = .29, p = .000). Serum alkaline
phosphatase was positively correlated with serum
homocysteine (r = .19, p = .020), PHT monotherapy
(r = .16, p = .041) and negatively correlated withVPA monotherapy (r = .16, p = .049). Serum homo-
cysteine was inversely correlated with s-FA
(r = .33, p = .000) and s-B12 (r = .18, p = .035).
Regression analyses
Regression models were developed to predict bone
mineral density and DEXA T scores at the spine and
hip using multiple linear regression, see Table 6. The
R2 scores for spine and hip mineral density were .12
and .48. The R2 values for spine and hip DEXA T
scores were .50 and .36. The regression models
reveal that different factors predict bone mineral
density and DEXA T score. Gender was a negative
predictor in females for spine T score and hip
mineral density, which follows accepted risk factors
for osteoporosis. Weight was a positive predictor for
spine mineral density and hip T score, while BMI (by
category) was a positive predictor of spine T score
and hip mineral density. For spine T score, ethnicity
was a positive predictor indicating that African
Americans and Latinos have better T scores than
Caucasians and Asians.
Use of calcium supplements was a negative pre-
dictor of spine T score. Menopausal status was a
negative predictor of hip mineral density. Present
use of alcohol was a positive predictor of hip mineral
density. Ambulatory status was a positive predictor
of hip mineral density and hip Tscore. The presence
of other risk factors (corticosteroid and thyroid
hormone use, eating disorders and cancer treat-
ment) was only a predictor for hip T score. Number
of years on AEDs was a negative predictor of spine T
score. Present use of an enzyme-inducing AED was a
negative predictor of spine mineral density and
spine T score. Present use of PHT monotherapy
was found to be a positive predictor of spine mineral
density, while LTG monotherapy was a negative
predictor of spine T score and hip mineral density.
History of fracture, BUN, serum alkaline phospha-
tase and log converted serum homocysteine were all
negative predictors of spine T score. Serum Hcy
when separated by quartiles positively predicts
spine T score. Age was also not a predictor in any
of the models. Also, the use of other AEDs (CBZ or
VPA) as monotherapy did not factor into any of the
regression models.Discussion
The medical literature over the past thirty years has
established a strong link between antiepileptic
medications and metabolic bone loss;49 however
the emphasis has primarily been on determining
which AEDs are worse for bone density in various
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mendations for DEXA screening and supplementa-
tion with calcium and Vitamin D.50 This is the first
study to look at homocysteine and bone loss in
epilepsy. In this study, log transformed values of
s-Hcy appear to predict spine T score. A trend
towards increased fractures in the higher quartiles
appears possible; however this may be due to the
statistically significant increase in subject age in
successive quartiles. Goldbahar et al., found nega-
tive correlations between log homocysteine and
bone mineral density in both the spine and hip,
but the effect was not predictive in their final
regression models.31 Their results revealed age,
menopause, BMI, alkaline phosphatase, creatinine
and folate were predictors. Several of these factors
also appear in of the predictive models in this study.
Higher levels of blood urea nitrogen in the succes-
sive quartiles, while still in the normal range, may
indicate changes in kidney function as a potential
factor in elevated homocysteine for epilepsy. This
finding is interesting since BUN made it to the final
predictionmodel for spine Tscore and homocysteine
levels are known to predict renal function loss and
cardiovascular events in end-stage renal disease.51
A correlation between serum folate and serum
homocysteine was evident in the bivariate analysis,
which supports the current epilepsy literature.52 In
the present study patients who reported supple-
mentation had significantly lower serum homocys-
teine supporting the possibility of an increased need
for folate in those taking AEDs, despite normal
folate levels. Additionally, patients taking multivi-
tamins were compared to those who were not. Since
nutritional supplements are recommended as part
of clinical care this demonstrates that multivitamins
can reduce serum homocysteine levels in persons
taking AEDs by approximately 25% (9.11 versus
12.3), supporting previous work by Yoo and Hong,
see Table 4.28
While an average serum homocysteine level of
10.7 mmol/L in our subjects is considered accepta-
ble by most laboratories there is evidence that
homocysteine levels within the range currently con-
sidered to be normal, the risk for coronary disease
rises, regardless of age and sex, with no threshold
effect.53 A recent analysis of NHANES by the Centers
for Disease Control, looking at post folate fortifica-
tion of foods, found 78% of the US population had
homocysteine levels below 9 mmol/ug.45 In this
study, over 50% of subjects had homocysteine levels
above this level. This is of concern since over half of
our patients reported taking a multivitamin. Based
on our data, the trend for elevated s-Hcy in the non-
Caucasian population may also be related to ethni-
city and/or related dietary habits.There were no significant differences in DEXA T-
scores in the univariate dependent variable analysis
based on ethnicity or gender, which is contrary to
generally accepted risk factors for fracture. How-
ever, when the multivariate regression analysis was
performed ethnicity was found to be a positive
predictor of spine T score, while gender was a
negative predictor supporting the generally
accepted increased risk of osteoporosis for Cauca-
sians and women.
This study also supports previous research that
mechanisms of bone loss in epilepsy appear to be
related to the use of enzyme-inducing AEDs and
elevated levels of alkaline phosphatase. While
changes in calcium have been suggested as mechan-
isms of AED-induced bone loss49 it is important to
note that serum calcium was normal in our subjects
despite reaching statistical significance in some
analyses shown in Table 4. Since we did not assess
Vitamin D status or parathyroid hormone levels in
this study we cannot say this precludes the presence
of Vitamin D deficiency or compensatory hyperpar-
athyroidism as a cause of the bone loss, especially
since normal calcium levels may be present in these
cases.
A recent study found subjects on lamotrigine or
valproate monotherapy had less negative effects on
bone markers and improved bone density compared
to phenytoin and carbamazepine monotherapy.16
Our data on DEXA spine and hip T scores, while
not significant, support a similar pattern. Interest-
ingly, in the multivariate analysis lamotrigine was
found to be a negative predictor of spine Tscore and
hip mineral density. While lamotrigine has anti-
folate properties it is unlikely this fully explains
our results. Since the mean length of AED exposure
in this study was 25 years it more likely that previous
exposure to other AEDs may be to blame. In review-
ing the individuals on LTGmonotherapy the majority
were Caucasian (9 of 16) and female (10 of 16),
which is likely a reflection of current prescribing
recommendations. There were no differences based
on age, weight, BMI and years on AEDs in the LTG
monotherapy group. Also, contrary to published
research we found PHTmonotherapy to be a positive
predictor of spine mineral density. A similar analysis
for the LTG group was performed and themajority of
individuals taking PHT monotherapy were African
American (13 of 17) and male (9 of 17) who are
generally less likely to experience bone loss. Again
there were no differences based on age, weight, BMI
and years on AEDs.
Weight and body mass index appear to be sig-
nificant predictors of bonemineral density and DEXA
T scores in person with epilepsy. However, short of
promoting obesity for the prevention of osteoporosis
32 J.O. Elliott et al.it makes sense that more beneficial health strate-
gies such as exercise, nutritional supplementation
and possibly bisphosphonates be recommended–—
especially to those who are very thin. Interestingly,
present alcohol consumption was found to be a
positive predictor of hip mineral density. While
alcoholism has a negative effect on bone,54 moder-
ate intake in the literature appears to be protec-
tive.55,56
Not surprisingly, additional factors found in the
multivariate analysis such as menopause status,
other risk factors, use of calcium supplements and
history of fracture support their ability to predict
DEXATscores or bone mineral density. Years on AEDs
do not consistently predict bone density or DEXA T
scores. This supports previous research that AEDs
affect bone health rather quickly. Since ambulatory
status is a positive predictor of hip mineral density
and hip T score it supports the importance of phy-
sical activity for reducing fracture risk.57,58 While
bone mineral density is most developed in childhood
and adolescence59 exercise is still vital throughout
adulthood especially in persons taking seizure med-
ications.
Limitations
The use of a retrospective, cross-sectional design
(without controls) may have prevented us from
detecting some effects, especially since almost half
of the subjects took multivitamins. This study also
included some older individuals with a diagnosis of
epilepsy at mid-life who may have bone loss irre-
spective of AED use. Also, length of time subjects
were on each AED was not available from chart
review. Any determination of a time-dependent
effect of AEDs on bone density would have to be
based on strict historical documentation or through
a prospective design. The comparisons of different
monotherapies provide some additional insight, but
again using only length of years on AEDs limits our
ability to generalize this study. Additionally, while a
majority of the DEXA scans and blood test results
were from the same facilities some results came
from outside labs whose equipment and methodol-
ogies may vary. The majority of DEXA reports pro-
vided only Tscore so no analysis could be performed
using Z scores.
An assessment of Vitamin D level would have been
useful in reporting our results in comparison with
other studies. While a study of Vitamin D would have
been beneficial in this population, Vitamin D status
had not been obtained on a routine basis over the
past few years due to the poor reliability of Vitamin
D assays and unreliable normal ranges suggested in
the literature.60,61 Insurance reimbursement forVitamin D studies was also a concern. This study
does not diminish the importance of Vitamin D in
persons taking AED but adds support to the litera-
ture for other potential markers.Conclusion
It appears that AEDs negatively affect bone density
regardless of race or gender. African Americans and
those of Latino background are generally thought to
have significantly less risk for fracture. Little in the
way of ethnicity data have been presented in the
literature on AED induced bone loss. It appears from
our data that African Americans with epilepsy have a
reduction in their bone density similar to Cauca-
sians. In contrast, Latinos may experience the least
bone loss from AEDs. In this study, AED-induced bone
loss was similar in both men and women. Therefore,
further research and recommendations for preven-
tion need to include men.
Diagnosis by DEXA scan improves the adoption of
certain behaviors, increases interest in knowledge
of calcium in foods and increases the use of calcium
supplements.62 For persons with childhood exposure
to AEDs, greater than 5 years of adult AED use
(especially enzyme-inducing AEDs), and for women
over age 50 (regardless of length of AED use) a DEXA
should be recommended.
Six AEDs (PHT, CBZ, PB, PRM, OXC, LTG) have
known anti-folate mechanisms in pregnancy, cardi-
ovascular protection and bone loss. Based on the
safety of calcium, Vitamin D and multivitamin sup-
plementation they continue to be important for
preventative care in this population. The prospect
of long term use of bisphosphonates may not be as
benign. Currently, no studies are available to sup-
port their use in preventing or treating AED-induced
bone loss. Until clinical guidelines can be supported
by evidence-based research, clinicians will have to
weight the risks and benefits on an individualized
basis.Implications for practice
It is standard practice at the Temple University
epilepsy clinic is to address bone health and nutri-
tion with all patients and to communicate treat-
ment issues to primary care physicians. This involves
gathering a list of medications and supplements at
each visit as part of a standardized visit flow sheet.
The importance of taking a standard multivitamin/
mineral supplement and calcium with Vitamin D
in relation to bone health is discussed with each
patient. Risk factors such as smoking, alcohol
Homocysteine and bone loss in epilepsy 33consumption, small frame, low body weight and
menopausal status are also discussed when clinically
appropriate. Prescriptions for the DEXA, lab tests
and any specific supplements are provided to
patients as necessary. Recommendations for supple-
ments include: calcium 1000 mg daily, a multivita-
min that contains 400 units of Vitamin D and folic
acid 1 mg (or more) for women of childbearing
potential. Exercise is recommended to patients
based on their neurologic status. Dietary recom-
mendations include a diet rich in dairy products,
fish, beans, leafy greens and nuts/seeds.References
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